Important Notice

This site is intended for US Healthcare Professionals only.

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diptheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diptheria toxoid-, or pertussis is antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine, is a contraindication.

Stock one Tdap* vaccine for all your eligible patients.
BOOSTRIX is the ONLY Tdap vaccine approved by the FDA† for adults 65 years of age and older."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"1,2

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diptheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diptheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine, is a contraindication.

Adacel® is only indicated for patients 10-64 years of age."toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"2

  • *Tetanus, diptheria, and acellular pertussis.
  • †U.S. Food and Drug Administration
  • Adacel is a registered trademark of Sanofi Pasteur group, and its subsidiaries.
  • Trademarks are owned by or licensed to the GSK group of companies
Make sure you have enough BOOSTRIX on hand
Visit www.gskdirect.com

Indication for BOOSTRIX

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.

Important Safety Information for BOOSTRIX

  • Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
  • The tip caps of the prefilled syringes for BOOSTRIX contain natural rubber latex, which may cause allergic reactions
  • The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
  • Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
  • Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
  • In clinical studies, common adverse reactions were pain, redness, and swelling at the injection site, increase in arm circumference of injected arm, headache, fatigue, gastrointestinal symptoms, and fever
  • Vaccination with BOOSTRIX may not result in protection in all vaccine recipients

References

"toolbar=yes, scrollbars=yes, resizable=yes, width=400, height=400,top=50, left=50"View all references

825072R0 October 2017

Chat